Results 91 to 100 of about 20,735 (212)

Adverse events after first and second doses of COVID-19 vaccination in England: a national vaccine surveillance platform self-controlled case series study [PDF]

, 2023
Objectives: To estimate the incidence of adverse events of interest (AEIs) after receiving their first and second doses of coronavirus disease 2019 (COVID-19) vaccinations, and to report the safety profile differences between the different COVID-19 ...
Agrawal, Utkarsh, Akbari, Ashley, Anand, Sneha N, Beggs, Jillian, Bradley, Declan T, Byford, Rachel, Chuter, Antony, Hinton, William, Howsam, Gary, Joy, Mark, Kar, Debasish, Lusignan, Simon de, Mayor, Nikhil, Murphy, Siobhan, Owen, Rhiannon K, O’Reilly, Dermot, Richard Hobbs, FD, Robertson, Chris, Sheikh, Aziz, Tsang, Ruby SM, Victor, William, Williams, John   +21 more
core   +2 more sources

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination

APIK Journal of Internal Medicine, 2022
Abstract IgA vasculitis (IgAV), a small-vessel vasculitis, is more frequently seen in children than in adults. IgAV is triggered by various bacterial and viral infective agents. Here, we are describing a case of IgAV following ChAdOx1 nCoV-19 vaccination. A 39-year-old male presented with skin rash, joint pain, and pain abdomen.
Manabendra Basu, P M Prathibha, B V Murali Mohan   +2 more
openaire   +2 more sources

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination

Vaccines, 2022
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples
Simone Barocci, Chiara Orlandi, Aurora Diotallevi, Gloria Buffi, Marcello Ceccarelli, Daniela Vandini, Eugenio Carlotti, Luca Galluzzi, Marco Bruno Luigi Rocchi, Mauro Magnani, Anna Casabianca   +10 more
doaj   +1 more source

Randomised, double-blind, controlled phase 1 trial of the candidate tuberculosis vaccine ChAdOx1-85A delivered by aerosol versus intramuscular route. [PDF]

A BCG booster vaccination administered via the respiratory mucosa may establish protective immune responses at the primary site of Mycobacterium tuberculosis infection.
Audran, R., Cavassini, M., Donnet, L., Fares, F., Fayet-Mello, A., Karoui, O., Lovis, A., McShane, H., Noirez, L., Satti, I., Soumas, V., Spertini, F.   +11 more
core   +2 more sources

Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia after a second ChAdOx1 nCoV-19 dose. [PDF]

, 2022
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.
Aguiar de Sousa, Diana, Arnold, Marcel, Bode, Felix J, Coutinho, Jonathan M, Ferro, Jose M, Frisullo, Giovanni, Heldner, Mirjam R., Karapanayiotides, Theodoros, Kremer Hovinga, Johanna Anna, Krzywicka, Katarzyna, Pötzsch, Bernd, Sanchez Van Kammen, Mayte, van de Munckhof, Anita, Zimmerman, Julian   +13 more
core   +2 more sources

Reactogenicity after heterologous mRNA/ChAdOx1 COVID-19-vaccination compared to homologous mRNA/mRNA and ChAdOx1/ChAdOx1 vaccination regimens: Descriptive interim results of a comparative observational cohort study

, 2022
Background and status of (inter)national research: An association between the administration of the COVID-19 vaccine ChAdOx1 (AstraZeneca) and the occasional occurrence of thromboembolic events has been detected as of March 2021. For individuals having received one dose of ChAdOx1, several countries [for full text, please go to the a.m. URL]
Warkentin, L, Lippert, N, Sebastiao, M, Kühlein, T, Kaiser, I, Gall, C, Steininger, P, Überla, K, Hueber, S   +8 more
openaire   +2 more sources

Thrombotic thrombocytopenia following ChAdOx1 nCov-19 vaccination

Acute Medicine Journal, 2021
Serious thromboembolic events with concurrent thrombocytopenia, sometimes accompanied by bleeding, have occurred very rarely following administration of the ChAdOx1 nCoV-19 vaccine. We report the case of a 59-year-old male with an unremarkable medical history who presented to the emergency department with increasing breathlessness five days after ...
A Jafri, A Prieto
openaire   +2 more sources

Classification of Platelet‐Activating Anti‐Platelet Factor 4 Disorders

International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 259-271, April 2026.
ABSTRACT Introduction The prototypic anti‐platelet factor 4 (PF4) disorder—heparin‐induced thrombocytopenia and thrombosis (HITT)—features immunoglobulin G (IgG) class antibodies that activate platelets, monocytes, and neutrophils in a mainly heparin‐dependent fashion via Fcγ receptor‐dependent cellular activation.
Theodore E. Warkentin
wiley   +1 more source

Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model

Frontiers in Immunology, 2020
Mayaro (MAYV) and chikungunya viruses (CHIKV) are vector-borne arthritogenic alphaviruses that cause acute febrile illnesses. CHIKV is widespread and has recently caused large urban outbreaks, whereas the distribution of MAYV is restricted to tropical ...
Rafael Kroon Campos, Lorena Preciado-Llanes, Sasha R. Azar, Young Chan Kim, Olivia Brandon, César López-Camacho, Arturo Reyes-Sandoval, Shannan L. Rossi, Shannan L. Rossi   +8 more
doaj   +1 more source

Preclinical immunogenicity of an adenovirus-vectored vaccine for herpes zoster

Human Vaccines & Immunotherapeutics, 2023
Herpes zoster (HZ) results from waning immunity following childhood infection with varicella zoster virus (VZV) but is preventable by vaccination with recombinant HZ vaccine or live HZ vaccine (two doses or one dose, respectively).
Marta Ulaszewska, Sarah Merelie, Sarah Sebastian, Teresa Lambe   +3 more
doaj   +1 more source